New clinical data reveals that oral semaglutide (Wegovy pill) offers greater weight loss efficacy and significantly better GI tolerability than orforglipron.
Eli Lilly has announced positive late-stage trial results for orforglipron, its investigational once-daily oral GLP-1 drug. In Phase 3 studies, orforglipron demonstrated superior blood sugar control and significant weight loss in adults with type 2 diabetes, outperforming other existing medications. These results position it as a potential new standard of care and a convenient oral alternative to injectable treatments.
Eli Lilly announced results from the Phase 3 ATTAIN-2 trial, where its oral GLP-1 receptor agonist orforglipron provided substantial weight loss and improved A1C for adults living with obesity and type 2 diabetes demonstrating efficacy and safety consistent with injectable medicines, and moving toward regulatory approval.
